ESG dedicated funds have delivered sustainable results in the last few years. So, should they form a part of your portfolio?

The level of 8,900 holds the key and at higher side, the level of 9,132 is likely to act as an immediate hurdle. Holding above this level, could lead to the further round of upmove towards the level of 9,350-9,400 in the near term. Stocks in news: Motherson Sumi, Dr Reddy’s Laboratories, Biocon, Hindalco Industries, Maruti Suzuki, Hero Motocorp.

On Wednesday morning, SGX Nifty is trading above 9,200-mark, indicating a gap-up start for the index; however, we feel the upmove may be restricted as the zone of 9,350-9,400 is a big hurdle to cross. On the earnings front, Wipro is slated to announce its Q4 numbers today.

On Tuesday, Dr Reddy’s Laboratories Ltd along with its subsidiaries announced the launch of an authorised generic version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. NitroDur is a trademark of USpharma Ltd.

The shares of Zee Entertainment Enterprises Limited (ZEEL) slipped more than eight per cent on Monday after the company recently announced that it has invested Rs 522 crore in its tech subsidiary, Margo Networks Private Limited.

On the capex front, the company has incurred the highest-ever capital expenditure in FY20, amounting to Rs 230 crore. Also, more than 10 new products have been developed for aero space, navy and energy sectors.

As part of its ongoing initiatives towards COVID-19 relief efforts, Hero MotoCorp, world’s largest manufacturer of motorcycles and scooters, is donating 60 first-responder mobile ambulances to authorities.

Tata Communications Limited has announced that the company will consider fundraising in its board meeting scheduled on April 15, 2020.

A leading private dairy in South India and a subsidiary of Godrej Agrovet Limited-Creamline Dairy Products Limited (CDPL) announced that it is delivering essential items like dairy products under their ‘Jersey’ portfolio in housing societies amid nationwide lockdown.

Biocon Limited and Mylan NV together have launched Fulphila, a biosimilar of Neulasta (pegfilgrastim) in Australia. Fulphila is now available on the pharmaceutical benefits scheme (PBS).